Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Chong-Xian Pan, M.D., Ph.D.


The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
  1. I01 BX006075 (Pan, Chong-xian) Apr 1, 2023 - Mar 31, 2027
    VA Collaborative Merit Review Award
    Translational Research to improve the care of advanced bladder cancer
    Role Description: This collaborative award includes several projects to address the unmet needs of chemotherapy, immunotherapy and targeted therapy of advanced bladder cancer
    Role: PI
  2. CA210189 (Pan, Chong-xian) Jul 1, 2022 - Jun 30, 2025
    Department of Defense PRCRP IMPACT
    Quadrifunctional Cancer-Specific Microtheranostic Platform for the Management of Bladder Cancer
    Role Description: The major goal of this project is to develop a microtheranostic platform that combine photodynamic diagnosis and therapy, microbiotherapy and local immunotherapy in the same platform for intravesical instillation into the bladder cavity
    Role: PI
  3. 21VAL001 (Pan, Chong-xian) Jul 1, 2021 - Jun 30, 2026
    Prostate Cancer Foundation
    Blavatnik Family Foundation Precision Oncology Center of Excellence (COE) at VABHS-Dana-Farber Cancer Institute
    Role Description: The goal of this project is to establish VABHS as a regional precision oncology center for prostate cancer and provide cares to veterans with prostate cancer
    Role: PI
  4. I01CX002247 (PAN, CHONG-XIAN) Oct 1, 2020 - Sep 30, 2024
    A Phase I trial of cancer-targeting micelles for non-myoinvasive bladder cancer
    Role: Principal Investigator
  5. W81XWH-19-1-0204 (Lam, Kit S) Jul 1, 2019 - Jun 30, 2023
    DoD Peer Reviewed Medical Research Program Expansion 3
    Delivery of targeting nano-photo-imiquimod to enhance response rate of advanced bladder cancer to check point blockade antibody therapy
    Role Description: The major goal is to develop bladder cancer-specific nanoporphyrin that can specifically delivery immunostimulator imiquimod to the bladder cancer, and potentiate photodynamic therapy and immunotherapy.
    Role: Co-PI

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Pan's Networks
Click the
buttons for more information and interactive visualizations!
Concepts (245)
Co-Authors (15)
Similar People (60)
Same Department 
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.